Novartis

Novartis Pharmaceuticals

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

2998

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Novartis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:34 UTC. Showing 200 of 2998. Open this list on ClinicalTrials.gov

N/A
NCT07928037 · A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer Patients
Novartis Pharmaceuticals · not yet recruiting · Metastatic Castration-Resistant Prostate Cancer · study director
N/A
NCT07920315 · Remibrutinib in Real-world Clinical Practice - a South Korea Sub-Study
Novartis Pharmaceuticals · not yet recruiting · Chronic Spontaneous Urticaria · study director
N/A
NCT07896746 · Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
Novartis Pharmaceuticals · not yet recruiting · Malaria · study director
N/A
NCT07881783 · A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Novartis Pharmaceuticals · not yet recruiting · Plaque Psoriasis · study director
Ph3
NCT07850752 · A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy
Novartis Pharmaceuticals · not yet recruiting · IgA Nephropathy (IgAN) · study director
N/A
NCT07844070 · A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy
Novartis Pharmaceuticals · active not recruiting · Multiple Sclerosis · study director
N/A
NCT07843758 · An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine Care
Novartis Pharmaceuticals · completed · Castration-Resistant Prostatic Cancer · study director
N/A
NCT07839858 · A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
Novartis Pharmaceuticals · completed · Polycythemia Vera · study director
Ph2
NCT07830719 · Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
Novartis Pharmaceuticals · recruiting · Coronary Artery Disease · study director
N/A
NCT07821411 · A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
Novartis Pharmaceuticals · active not recruiting · Multiple Sclerosis · study director
Ph1
NCT07809919 · A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects
Novartis Pharmaceuticals · completed · Visceral Leishmaniasis, Chagas Disease · study director
N/A
NCT07805408 · A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients
Novartis Pharmaceuticals · completed · Immune Thrombocytopenia · study director
Ph1
NCT07797322 · A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function
Novartis Pharmaceuticals · recruiting · Participants With Moderate and Severe Renal Impairment and Healthy Participants · study director
N/A
NCT07786077 · A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Novartis Pharmaceuticals · recruiting · Primary Immune Thrombocytopenia · study director
N/A
NCT07779460 · A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
Novartis Pharmaceuticals · recruiting · Multiple Sclerosis · study director
Ph2
NCT07775924 · A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
Novartis Pharmaceuticals · recruiting · Cutaneous Lichen Planus · study director
N/A
NCT07770074 · A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
Novartis Pharmaceuticals · not yet recruiting · Radioiodine-refractory Differentiated Thyroid Cancer · study director
N/A
NCT07767877 · A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies
Novartis Pharmaceuticals · not yet recruiting · Vascular Anomalies · study director
Ph3
NCT07768371 · A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
Novartis Pharmaceuticals · recruiting · IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy · study director
N/A
NCT07767890 · A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients
Novartis Pharmaceuticals · recruiting · Spinal Muscular Atrophy · study director
N/A
NCT07760714 · A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients
Novartis Pharmaceuticals · completed · Breast Cancer · study director
N/A
NCT07757048 · A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States
Novartis Pharmaceuticals · completed · IGA Nephropathy · study director
N/A
NCT07743281 · A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse
Novartis Pharmaceuticals · completed · Multiple Sclerosis · study director
N/A
NCT07737730 · A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Novartis Pharmaceuticals · not yet recruiting · Axial Spondyloarthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis · study director
N/A
NCT07737756 · A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia
Novartis Pharmaceuticals · not yet recruiting · Spinal Muscular Atrophy · study director
N/A
NCT07716410 · A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants
Novartis Pharmaceuticals · recruiting · Cryptosporidiosis · study director
N/A
NCT07710716 · A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients
Novartis Pharmaceuticals · active not recruiting · Breast Cancer · study director
N/A
NCT07697989 · Pluvicto Real-world Investigation in Survival in Metastatic CRPC
Novartis Pharmaceuticals · recruiting · Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis · study director
N/A
NCT07690319 · A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Novartis Pharmaceuticals · not yet recruiting · Hidradenitis Suppurativa · study director
N/A
NCT07683065 · A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Novartis Pharmaceuticals · recruiting · Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease · study director
Ph4
NCT07684469 · Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
Novartis Pharmaceuticals · not yet recruiting · Acute Coronary Syndrome · study director
N/A
NCT07681258 · A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Novartis Pharmaceuticals · not yet recruiting · Chronic Myeloid Leukemia · study director
Ph2
NCT07679269 · Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Novartis Pharmaceuticals · not yet recruiting · PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) · study director
N/A
NCT07677254 · A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Novartis Pharmaceuticals · recruiting · Prostatic Neoplasms, Castration-Resistant · study director
N/A
NCT07677267 · A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Novartis Pharmaceuticals · recruiting · Prostatic Neoplasms, Castration-Resistant · study director
Ph2
NCT07660172 · A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Novartis Pharmaceuticals · not yet recruiting · Primary Immune Thrombocytopenia (ITP) · study director
N/A
NCT07653126 · A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
Novartis Pharmaceuticals · completed · Gastro-enteropancreatic Neuroendocrine Tumor · study director
N/A
NCT07649252 · A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan
Novartis Pharmaceuticals · completed · Melanoma · study director
N/A
NCT07647042 · A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors
Novartis Pharmaceuticals · completed · Breast Cancer · study director
Ph1
NCT07644364 · HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension
Novartis Pharmaceuticals · recruiting · Elevated Blood Pressure, Hypertension · study director
N/A
NCT07644351 · A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients
Novartis Pharmaceuticals · completed · Acute Lymphoblastic Leukemia · study director
N/A
NCT07642557 · Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
Novartis Pharmaceuticals · recruiting · Chronic Spontaneous Urticaria · study director
N/A
NCT07635316 · A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Novartis Pharmaceuticals · recruiting · Gastroenteropancreatic Neuroendocrine Tumor · study director
Ph3
NCT07625306 · Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
Novartis Pharmaceuticals · withdrawn · Acute Coronary Syndrome (ACS) · study director
Ph1
NCT07626281 · Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
Novartis Pharmaceuticals · recruiting · Inclisiran Formulation · study director
Ph2
NCT07610278 · A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Novartis Pharmaceuticals · recruiting · Hypercholesterolaemia · study director
N/A
NCT07598448 · A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain
Novartis Pharmaceuticals · recruiting · Complement 3 Glomerulopathy · study director
N/A
NCT07598422 · A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
Novartis Pharmaceuticals · recruiting · Schnitzler Syndrome · study director
N/A
NCT07594587 · A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Novartis Pharmaceuticals · recruiting · Graft-Versus-Host Disease · study director
N/A
NCT07587723 · A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
Novartis Pharmaceuticals · recruiting · Immune Thrombocytopenia · study director
N/A
NCT07566988 · A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
Novartis Pharmaceuticals · completed · Multiple Sclerosis · study director
N/A
NCT07554547 · Crizanlizumab Pregnancy Outcomes Intensive Monitoring
Novartis Pharmaceuticals · completed · Sickle Cell Disease · study director
N/A
NCT07549516 · A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
Novartis Pharmaceuticals · recruiting · Leukemia, Chronic Myeloid · study director
N/A
NCT07543731 · A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Novartis Pharmaceuticals · recruiting · Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia, Familial · study director
Ph2
NCT07543120 · An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Novartis Pharmaceuticals · recruiting · Hypertension (HTN) · study director
N/A
NCT07543419 · Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
Novartis Pharmaceuticals · recruiting · Hidradenitis Suppurativa · study director
N/A
NCT07527767 · Secondary Use of PARALLEL-HF Data
Novartis Pharmaceuticals · completed · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF) · study director
Ph3
NCT07517263 · An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Novartis Pharmaceuticals · active not recruiting · Cardiovascular Disease and Lipoprotein(a) · study director
N/A
NCT07517250 · A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Novartis Pharmaceuticals · recruiting · Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis · study director
N/A
NCT07512063 · A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
Novartis Pharmaceuticals · completed · Breast Cancer · study director
N/A
NCT07508007 · Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Novartis Pharmaceuticals · recruiting · Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice · study director
N/A
NCT07504783 · A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
Novartis Pharmaceuticals · completed · Multiple Sclerosis · study director
Ph3
NCT07498335 · Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Novartis Pharmaceuticals · recruiting · Berger Disease, Bergers Disease, IgA Nephropathy · study director
N/A
NCT07498413 · Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
Novartis Pharmaceuticals · completed · Breast Cancer · study director
Ph4
NCT07489573 · Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Novartis Pharmaceuticals · recruiting · Hidradenitis Suppurativa (HS) · study director
N/A
NCT07484269 · PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
Novartis Pharmaceuticals · recruiting · Metastatic Prostate Cancer · study director
N/A
NCT07481084 · IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection
Novartis Pharmaceuticals · not yet recruiting · IgA Nephropathy · study director
N/A
NCT07477756 · A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Novartis Pharmaceuticals · completed · Prostate Cancer · study director
N/A
NCT07476170 · Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
Novartis Pharmaceuticals · recruiting · HR+/HER2- Advanced or Metastatic Breast Cancer · study director
N/A
NCT07474311 · A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy
Novartis Pharmaceuticals · completed · Muscular Atrophy, Spinal · study director
N/A
NCT07465666 · A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Novartis Pharmaceuticals · recruiting · Hypertension · study director
Ph1
NCT07465653 · A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Novartis Pharmaceuticals · recruiting · Heart Failure With Reduced Ejection Fraction · study director
Ph1/Ph2
NCT07468071 · Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Novartis Pharmaceuticals · active not recruiting · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation · study director
N/A
NCT07465679 · A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Novartis Pharmaceuticals · completed · Heart Failure With Reduced Ejection Fraction · study director
N/A
NCT07468500 · Real World Adherence of PCSK9 Targeted Therapy
Novartis Pharmaceuticals · not yet recruiting · Dyslipidemia, Hypercholesterolemia · study director
Ph3
NCT07456891 · Remibrutinib Open Label Roll-over Post-trial Access Protocol
Novartis Pharmaceuticals · recruiting · Indication of the Parent Protocol · study director
N/A
NCT07454889 · A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Novartis Pharmaceuticals · not yet recruiting · Hidradenitis Suppurativa · study director
N/A
NCT07454850 · A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Novartis Pharmaceuticals · not yet recruiting · Leukemia, Myeloid, Chronic-Phase · study director
N/A
NCT07450157 · A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
Novartis Pharmaceuticals · completed · Prostate Cancer · study director
N/A
NCT07450170 · A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
Novartis Pharmaceuticals · completed · Chronic Urticaria · study director
Ph1
NCT07422610 · Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals · recruiting · Advanced Malignancies and Hepatic Impairment · study director
Ph2
NCT07421167 · A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals · recruiting · Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) · study director
N/A
NCT07416162 · A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
Novartis Pharmaceuticals · recruiting · Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy · study director
N/A
NCT07415083 · A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
Novartis Pharmaceuticals · completed · Aplastic Anemia · study director
N/A
NCT07409636 · A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
Novartis Pharmaceuticals · completed · Hypercholesterolemia, Mixed Dyslipidemia · study director
N/A
NCT07408219 · A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Novartis Pharmaceuticals · recruiting · Chronic Spontaneous Urticaria · study director
N/A
NCT07403214 · A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
Novartis Pharmaceuticals · completed · Muscular Atrophy, Spinal · study director
Ph1/Ph2
NCT07387926 · Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals · recruiting · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · study director
N/A
NCT07378943 · A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
Novartis Pharmaceuticals · completed · Muscular Atrophy, Spinal · study director
N/A
NCT07378969 · A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
Novartis Pharmaceuticals · recruiting · Secondary Malignancies of T-cell Origin · study director
N/A
NCT07375355 · Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Novartis Pharmaceuticals · recruiting · Chronic Myeloid Leukemia in Chronic Phase · study director
N/A
NCT07376265 · A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
Novartis Pharmaceuticals · completed · Heart Failure · study director
N/A
NCT07374120 · Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
Novartis Pharmaceuticals · completed · Leukemia, Myeloid, Chronic-Phase · study director
N/A
NCT07363434 · A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
Novartis Pharmaceuticals · completed · Breast Cancer · study director
N/A
NCT07357441 · A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey
Novartis Pharmaceuticals · completed · Myelofibrosis · study director
Ph3
NCT07357727 · A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals · recruiting · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) · study director
N/A
NCT07358780 · Remibrutinib in Real-world Clinical Practice - a US Sub-study
Novartis Pharmaceuticals · recruiting · Chronic Spontaneous Urticaria · study director
N/A
NCT07358364 · Remibrutinib in Real-world Clinical Practice
Novartis Pharmaceuticals · recruiting · Chronic Spontaneous Urticaria · study director
Ph2
NCT07354074 · Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis Pharmaceuticals · recruiting · Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive · study director
Ph1
NCT07340190 · A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Novartis Pharmaceuticals · recruiting · Advanced Malignancies · study director
Ph1
NCT07340138 · Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Novartis Pharmaceuticals · active not recruiting · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) · study director
N/A
NCT07331259 · CHART-C3G/CLNP023B12011
Novartis Pharmaceuticals · not yet recruiting · C3 Glomerulopathy, Complement-mediated Kidney Disease, Proteinuria · study director
N/A
NCT07290270 · Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)
Novartis Pharmaceuticals · recruiting · Metastatic Prostate Cancer · study director
N/A
NCT07282015 · Real-world Secukinumab Outcomes in Canadian HS Patients
Novartis Pharmaceuticals · recruiting · Hidradenitis Suppurativa · study director
N/A
NCT07243782 · Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Novartis Pharmaceuticals · recruiting · Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis · study director
N/A
NCT07243002 · Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
Novartis Pharmaceuticals · recruiting · Breast Cancer · study director
Ph2
NCT07235046 · A Study of DII235 in Adults With Elevated Lipoprotein(a)
Novartis Pharmaceuticals · active not recruiting · Lipoprotein Disorder · study director
N/A
NCT07229235 · REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals · recruiting · Paroxysmal Nocturnal Hemoglobinuria (PNH) · study director
Ph1/Ph2
NCT07226986 · A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis Pharmaceuticals · recruiting · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy · study director
N/A
NCT07223476 · Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
Novartis Pharmaceuticals · completed · Breast Cancer · study director
N/A
NCT07222423 · A Study of the Epidemiology and Hospital Management of Patients With PROS in France
Novartis Pharmaceuticals · completed · PIK3CA-Related Overgrowth Spectrum · study director
N/A
NCT07217106 · A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure
Novartis Pharmaceuticals · completed · Heart Failure · study director
Ph2
NCT07217067 · A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
Novartis Pharmaceuticals · recruiting · Atrial Fibrillation · study director
N/A
NCT07214857 · Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Novartis Pharmaceuticals · completed · Cardiovascular Disease · study director
Ph1/Ph2
NCT07206056 · An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Novartis Pharmaceuticals · recruiting · Progressive Metastatic Castrate Resistant Prostate Cancer · study director
N/A
NCT07190053 · Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.
Novartis Pharmaceuticals · not yet recruiting · Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA) · study director
Ph1/Ph2
NCT07190300 · TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals · recruiting · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · study director
N/A
NCT07188428 · Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Novartis Pharmaceuticals · completed · Leukemia, Chronic Myeloid · study director
N/A
NCT07180238 · Concept Elicitation and Patient Experience Mapping in SA-AKI
Novartis Pharmaceuticals · completed · Sepsis-associated Acute Kidney Injury · study director
Ph1
NCT07174063 · A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Novartis Pharmaceuticals · active not recruiting · Metastatic Prostate Cancer (mCRPC) · study director
N/A
NCT07168694 · A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
Novartis Pharmaceuticals · completed · Secondary Progressive Multiple Sclerosis · study director
N/A
NCT07156149 · Fabhalta Capsules Specified Drug-use Survey
Novartis Pharmaceuticals · active not recruiting · C3 Glomerulopathy · study director
N/A
NCT07151820 · A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
Novartis Pharmaceuticals · completed · Leukemia, Chronic Myeloid · study director
N/A
NCT07150793 · A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan
Novartis Pharmaceuticals · completed · Myeloid Leukemia, Chronic · study director
N/A
NCT07148505 · A Study of Real-world Outcomes Among Patients Treated With Ribociclib
Novartis Pharmaceuticals · completed · Metastatic Breast Cancer · study director
Ph2
NCT07146906 · A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Novartis Pharmaceuticals · recruiting · Immunoglobulin A Nephropathy (IgAN) · study director
N/A
NCT07142265 · Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
Novartis Pharmaceuticals · recruiting · Myocardial Infarction · study director
N/A
NCT07103486 · A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Novartis Pharmaceuticals · completed · Diffuse Large B-Cell Lymphoma · study director
Ph3
NCT07102628 · Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Novartis Pharmaceuticals · recruiting · Acute Coronary Syndrome · study director
N/A
NCT07093801 · Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals · active not recruiting · Metastatic Castration Resistant Prostate Cancer · study director
N/A
NCT07091019 · A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
Novartis Pharmaceuticals · recruiting · Chronic Myelogenous Leukemia - Chronic Phase · study director
N/A
NCT07086196 · A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
Novartis Pharmaceuticals · completed · Metastatic HR+/HER2- Breast Cancer · study director
N/A
NCT07072013 · An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer
Novartis Pharmaceuticals · completed · Breast Cancer · study director
Ph2
NCT07047118 · A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals · active not recruiting · Prostatic Cancer, Castration-Resistant · study director
Ph2
NCT07039422 · Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Novartis Pharmaceuticals · withdrawn · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia · study director
N/A
NCT07039383 · A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
Novartis Pharmaceuticals · completed · Acute Lymphoblastic Leukemia · study director
N/A
NCT07036718 · NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
Novartis Pharmaceuticals · terminated · Paroxysmal Nocturnal Hemoglobinuria · study director
Ph4
NCT07034690 · Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Novartis Pharmaceuticals · recruiting · Atherosclerotic Cardiovascular Disease · study director
Ph1
NCT07032272 · A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.
Novartis Pharmaceuticals · completed · Autoimmune and Chronic Inflammatory Diseases · study director
N/A
NCT07029542 · Home Reported Outcomes in C3G Study
Novartis Pharmaceuticals · recruiting · C3 Glomerulopathy · study director
N/A
NCT07027163 · A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
Novartis Pharmaceuticals · completed · Food Hypersensitivity, Anaphylaxis · study director
N/A
NCT07023445 · Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
Novartis Pharmaceuticals · completed · Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia · study director
Ph2
NCT06997588 · EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals · recruiting · PIK3CA-related Overgrowth Spectrum (PROS) · study director
Ph3
NCT06994845 · Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Novartis Pharmaceuticals · recruiting · Primary Immunoglobulin A Nephropathy (IgAN) · study director
N/A
NCT06991894 · Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
Novartis Pharmaceuticals · completed · Anemia, Aplastic · study director
N/A
NCT06991608 · A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany
Novartis Pharmaceuticals · active not recruiting · Chronic Spontaneous Urticaria · study director
Ph2
NCT06991556 · An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals · active not recruiting · Metastatic Hormone-sensitive Prostate Cancer · study director
Ph4
NCT06941792 · Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
Novartis Pharmaceuticals · active not recruiting · Coronary Heart Disease · study director
Ph3
NCT06934967 · Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Novartis Pharmaceuticals · recruiting · Paroxysmal Nocturnal Hemoglobinuria (PNH) · study director
N/A
NCT06923124 · A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life
Novartis Pharmaceuticals · completed · Familial Mediterranean Fever · study director
N/A
NCT06897657 · A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
Novartis Pharmaceuticals · completed · Multiple Sclerosis, Relapsing-Remitting · study director
Ph2
NCT06894511 · An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Novartis Pharmaceuticals · active not recruiting · Metastatic Castration Resistant Prostate Cancer (mCRPC) · study director
Ph1/Ph2
NCT06881823 · Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Novartis Pharmaceuticals · withdrawn · Prostate Cancer · study director
Ph2
NCT06868290 · Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Novartis Pharmaceuticals · active not recruiting · ANCA Associated Vasculitis (AAV) · study director
Ph3
NCT06858319 · Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Novartis Pharmaceuticals · recruiting · Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases · study director
N/A
NCT06854341 · A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
Novartis Pharmaceuticals · completed · Multiple Sclerosis, Relapsing-Remitting · study director
Ph3
NCT06855277 · Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Novartis Pharmaceuticals · recruiting · Prostate Cancer · study director
Ph3
NCT06840392 · A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Novartis Pharmaceuticals · active not recruiting · Hidradenitis Suppurativa · study director
N/A
NCT06838143 · Ilaris NIS in Korea
Novartis Pharmaceuticals · recruiting · Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF) · study director
Ph4
NCT06824103 · Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals · recruiting · Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease · study director
Ph3
NCT06813911 · Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Novartis Pharmaceuticals · active not recruiting · Atherosclerotic Cardiovascular Disease (ASCVD) · study director
Ph3
NCT06799000 · A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Novartis Pharmaceuticals · active not recruiting · Hidradenitis Suppurativa · study director
N/A
NCT06797531 · RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
Novartis Pharmaceuticals · recruiting · HR+/HER2- Early Breast Cancer · study director
Ph2
NCT06797518 · Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Novartis Pharmaceuticals · recruiting · Glomerulonephritis, IGA, Immunoglobulin A Nephropathy · study director
N/A
NCT06785818 · Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis Pharmaceuticals · recruiting · B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma · study director
Ph3
NCT06784752 · Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Novartis Pharmaceuticals · recruiting · Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) · study director
N/A
NCT06760624 · Effectiveness of Ofatumumab in Real-world Practice
Novartis Pharmaceuticals · completed · Multiple Sclerosis · study director
N/A
NCT06737419 · Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Novartis Pharmaceuticals · completed · Multiple Sclerosis · study director
N/A
NCT06715254 · A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
Novartis Pharmaceuticals · terminated · Tuberculosis · study director
Ph3
NCT06711887 · Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Novartis Pharmaceuticals · recruiting · Lupus Nephritis · study director
Ph1/Ph2
NCT06704269 · Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis Pharmaceuticals · active not recruiting · Generalized Myasthenia Gravis · study director
N/A
NCT06705504 · A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
Novartis · completed · Hormone Receptor Positive HER-2 Negative Breast Cancer · study director
N/A
NCT06699914 · A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
Novartis Pharmaceuticals · completed · Neovascular Age-Related Macular Degeneration · study director
N/A
NCT06692803 · Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
Novartis Pharmaceuticals · completed · Chronic Myeloid Leukemia · study director
N/A
NCT06684964 · RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
Novartis Pharmaceuticals · recruiting · Chronic Myelogenous Leukemia in Chronic Phase · study director
N/A
NCT06683768 · A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
Novartis Pharmaceuticals · completed · Hypertension · study director
N/A
NCT06671314 · Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Novartis · completed · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction · study director
N/A
NCT06669221 · Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study
Novartis Pharmaceuticals · completed · Aplastic Anemia (AA) · study director
N/A
NCT06668324 · Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Novartis Pharmaceuticals · completed · Multiple Sclerosis · study director
N/A
NCT06666114 · Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
Novartis Pharmaceuticals · completed · Psoriasis (PsO), Psoriatic Arthritis (PsA) · study director
Ph2
NCT06665256 · Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Novartis Pharmaceuticals · active not recruiting · Idiopathic Inflammatory Myopathies · study director
N/A
NCT06662812 · Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
Novartis · completed · Sickle Cell Disease · study director
N/A
NCT06662825 · Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
Novartis · completed · Sickle Cell Disease · study director
Ph2
NCT06655896 · Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals · active not recruiting · Scleroderma, Diffuse · study director
Ph1/Ph2
NCT06649110 · A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals · recruiting · Healthy Volunteers, Pulmonary Arterial Hypertension · study director
Ph2
NCT06643481 · A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Novartis Pharmaceuticals · active not recruiting · Amyotrophic Lateral Sclerosis (ALS) · study director
N/A
NCT06644638 · Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
Novartis · completed · Multiple Sclerosis · study director
N/A
NCT06632730 · Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
Novartis · completed · Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II · study director
N/A
NCT06619704 · Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy
Novartis Pharmaceuticals · completed · Metastatic Breast Cancer · study director
Ph1/Ph2
NCT06617793 · An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Novartis Pharmaceuticals · active not recruiting · Relapsing Multiple Sclerosis · study director
N/A
NCT06606314 · Specified Drug-use Surveillance of Fabhalta Capsules
Novartis Pharmaceuticals · active not recruiting · Paroxysmal Nocturnal Hemoglobinuria · study director
N/A
NCT06604897 · Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
Novartis Pharmaceuticals · completed · Essential Hypertension · study director
N/A
NCT06595069 · A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
Novartis · completed · Hypercholesterolemia · study director
Ph3
NCT06597019 · Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals · recruiting · Familial Hypercholesterolemia - Heterozygous · study director
N/A
NCT06588387 · A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis
Novartis · completed · Secondary Progressive Multiple Sclerosis · study director
Ph3
NCT06597006 · Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Novartis Pharmaceuticals · recruiting · Familial Hypercholesterolemia - Homozygous · study director
N/A
NCT06600009 · Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
Novartis · completed · Psoriatic Arthritis · study director
Ph2
NCT06581198 · A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Novartis Pharmaceuticals · active not recruiting · Lupus Erythematosus, Systemic, Lupus Nephritis · study director
N/A
NCT06557291 · Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
Novartis · completed · BRAF V600 Mutated-Stage III/IV Melanoma · study director
Ph1
NCT06558097 · Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants
Novartis Pharmaceuticals · completed · XXB750 in Healthy Participants · study director

Grants

NIH projects from RePORTER, fetched 2026-11-11 19:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name.